Skandinaviska Enskilda Banken Ab (Publ) Madrigal Pharmaceuticals, Inc. Transaction History
Skandinaviska Enskilda Banken Ab (Publ)
- $21.6 Billion
- Q4 2024
A detailed history of Skandinaviska Enskilda Banken Ab (Publ) transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Skandinaviska Enskilda Banken Ab (Publ) holds 7,798 shares of MDGL stock, worth $2.72 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
7,798
Previous 8,955
12.92%
Holding current value
$2.72 Million
Previous $1.9 Million
26.63%
% of portfolio
0.01%
Previous 0.01%
Shares
6 transactions
Others Institutions Holding MDGL
# of Institutions
336Shares Held
22.3MCall Options Held
960KPut Options Held
940K-
Janus Henderson Group PLC London, X02.21MShares$769 Million0.36% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.04MShares$711 Million38.14% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.03MShares$707 Million9.12% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$695 Million10.03% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$688 Million6.75% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $5.96B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...